- Home
- RTO vs EXEL Comparison
RTO vs EXEL Comparison
Compare RTO & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RTO
- EXEL
- Stock Information
- Founded
- RTO 1925
- EXEL 1994
- Country
- RTO United Kingdom
- EXEL United States
- Employees
- RTO N/A
- EXEL N/A
- Industry
- RTO Business Services
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RTO Consumer Discretionary
- EXEL Health Care
- Exchange
- RTO Nasdaq
- EXEL Nasdaq
- Market Cap
- RTO 12.0B
- EXEL 11.1B
- IPO Year
- RTO N/A
- EXEL 2000
- Fundamental
- Price
- RTO $26.30
- EXEL $42.55
- Analyst Decision
- RTO Buy
- EXEL Buy
- Analyst Count
- RTO 1
- EXEL 24
- Target Price
- RTO N/A
- EXEL $44.73
- AVG Volume (30 Days)
- RTO 1.0M
- EXEL 2.8M
- Earning Date
- RTO 07-31-2025
- EXEL 11-04-2025
- Dividend Yield
- RTO 1.94%
- EXEL N/A
- EPS Growth
- RTO N/A
- EXEL 53.55
- EPS
- RTO 0.13
- EXEL 2.38
- Revenue
- RTO $7,581,860,530.00
- EXEL $2,288,218,000.00
- Revenue This Year
- RTO N/A
- EXEL $9.14
- Revenue Next Year
- RTO N/A
- EXEL $12.51
- P/E Ratio
- RTO $39.48
- EXEL $17.95
- Revenue Growth
- RTO N/A
- EXEL 9.93
- 52 Week Low
- RTO $19.60
- EXEL $31.90
- 52 Week High
- RTO $30.10
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- RTO 41.14
- EXEL 60.53
- Support Level
- RTO $26.46
- EXEL $41.23
- Resistance Level
- RTO $26.82
- EXEL $43.16
- Average True Range (ATR)
- RTO 0.43
- EXEL 1.47
- MACD
- RTO -0.23
- EXEL 0.29
- Stochastic Oscillator
- RTO 15.18
- EXEL 84.72
About RTO Rentokil Initial plc
Rentokil Initial is the largest global provider of route-based pest control and commercial hygiene services, operating in 89 countries. The group also offers a range of specialist route-based services, including office and commercial space plant care, property care, and workwear rentals. The group serves a diverse client base of global food producers, hotel chains, industrial goods companies, restaurants, and individual residential customers.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.